English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR

Sos, M., Koker, M., Weir, B., Heynck, S., Rabinovsky, R., Zander, T., et al. (2009). PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Research, 69(8), 3256-3261.

Item is

Files

show Files

Locators

show

Creators

show
hide
 Creators:
Sos, Martin1, Author           
Koker, Mirjam1, Author           
Weir, Barbara2, Author
Heynck, Stefanie1, Author           
Rabinovsky, Rosalia2, Author
Zander, Thomas3, Author           
Seeger, Jens M.2, Author
Weiss, Jonathan1, Author           
Fischer, Florian1, Author           
Frommolt, Peter2, Author
Michel, Kathrin1, Author           
Peifer, Martin1, Author           
Mermel, Craig2, Author
Girard, Luc2, Author
Peyton, Michael2, Author
Gazdar, Adi F.2, Author
Minna, John D.2, Author
Garraway, Levi A.2, Author
Kashkar, Hamid2, Author
Pao, William2, Author
Meyerson, Matthew2, AuthorThomas, Roman K.1, Author            more..
Affiliations:
1Funktionelle Krebsgenomforschung, Junior Research Groups, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149656              
21. Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA 2. Univ Texas SW Med Ctr Dallas, Dept Internal Med & Pharmacol, Dallas, TX 75390 USA 3. Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA 4. Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA 5. Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA 6. Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA, ou_persistent22              
3Klinisches PET, Neurologische Abteilung, Max-Planck-Institut für neurologische Forschung, Managing Director: D. Yves von Cramon, Max Planck Institute for Metabolism Research, Managing Director: Jens Brüning, Max Planck Society, ou_2149663              

Content

show

Details

show
hide
Language(s): eng - English
 Dates: 2009-04
 Publication Status: Published in print
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: Peer
 Identifiers: eDoc: 418492
ISI: 000265314900004
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Cancer Research
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: -
Pages: - Volume / Issue: 69 (8) Sequence Number: - Start / End Page: 3256 - 3261 Identifier: ISSN: 0008-5472